Resistance of Gram-Negative Bacteria to Eravacycline: A Systematic Review of Data from In Vitro Studies [PDF]
PathogensIntroduction: Eravacycline is a new fluorocycline antibiotic with a broad spectrum of antimicrobial activity approved for the treatment of patients with complicated intra-abdominal infections.
Matthew E. Falagas +4 more
doaj +5 more sources
Emergence of eravacycline heteroresistance in carbapenem-resistant Acinetobacter baumannii isolates in China [PDF]
Frontiers in Cellular and Infection MicrobiologyCarbapenem-resistant Acinetobacter baumannii (CRAB) is resistant to almost all antibiotics. Eravacycline, a newer treatment option, has the potential to treat CRAB infections, however, the mechanism by which CRAB isolates develop resistance to ...
Yi-tan Li +10 more
exaly +5 more sources
Stability indicating RP-HPLC method for quantification of Eravacycline and its impurities in Eravacycline for injection [PDF]
Journal of Chemical Health Risks, 2023 The main aim and objective of the research work is to develop an effective, sensitive, economical and simple reverse phase HPLC method for quantification of Eravacycline and its impurities in Eravacycline parenteral dosage form.
P.Venkata Prabhakara Rao, Syed Mastan Ali, P. Bharath, D.Ramachandran
core +3 more sources
Efficacy and safety of eravacycline: A meta-analysis
Journal of Global Antimicrobial Resistance, 2021 Objectives: This study was conducted to evaluate the efficacy and safety of eravacycline, a recently approved fluorocycline for treatment of complicated intra-abdominal infections (cIAIs).
Khalid Eljaaly +4 more
doaj +5 more sources
Eravacycline as Salvage Therapy for Severe Intra-Abdominal Infections Caused by Multidrug-Resistant Acinetobacter baumannii: A Case Series [PDF]
AntibioticsBackground/Objectives: Infections due to multidrug-resistant (MDR) Acinetobacter baumannii represent a critical challenge in modern healthcare, with limited therapeutic options.
Marcello Trizzino +10 more
doaj +2 more sources
Combating resistant pathogens: exploring the efficacy of eravacycline utilization in multidrug-resistant infections [PDF]
Microbiology SpectrumEravacycline, FDA-approved for complicated intra-abdominal infections, is increasingly used off-label for multidrug-resistant infections, including carbapenem-resistant Enterobacterales, Stenotrophomonas maltophilia, and carbapenem-resistant ...
Kiara Patino +4 more
doaj +2 more sources
Novel Tet(L) Efflux Pump Variants Conferring Resistance to Tigecycline and Eravacycline in Staphylococcus Spp. [PDF]
Microbiology Spectrum, 2021 Tigecycline is regarded as one of the few important last-resort antibiotics to treat complicated skin and intra-abdominal infections. Members of the genus Staphylococcus are zoonotic pathogens and pose a serious threat to public health.
Nannan Wang +5 more
doaj +3 more sources
Real-world effectiveness and predictors of treatment failure for eravacycline in patients with Acinetobacter baumannii or Klebsiella pneumoniae infections: a multicenter retrospective analysis [PDF]
Frontiers in Cellular and Infection MicrobiologyIntroductionEravacycline (ERV) is a novel synthetic fluorocycline antibiotic with broad-spectrum antibacterial efficacy against pathogens. This study aimed to investigate the clinical effectiveness of eravacycline and its correlation with minimum ...
Yi Li +5 more
doaj +2 more sources
Antibacterial activity of eravacycline against Klebsiella pneumoniae isolates: an in vitro study [PDF]
Microbiology SpectrumEravacycline, a novel tetracycline antibiotic, may be an effective treatment option for Klebsiella pneumoniae infections. We thus conducted an in vitro susceptibility analysis for eravacycline in 211 K. pneumoniae isolates.
Yuanzhi Gong +7 more
doaj +2 more sources
A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline
Infectious Diseases and Therapy, 2020 Background Eravacycline is a novel fluorocycline approved for treatment of intraabdominal infections, with a broad spectrum of activity against a range of pathogens including multidrug-resistant species, including ESBL- or KPC-producing isolates.
Nicholas Van Hise, Vishal Didwania
exaly +2 more sources